Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability